Physician profile
Raymund R David
NPI 1346216652
$30,686.64
in general payments reported to CMS, 2019-2025
43 companies · $5,178 in 2025
The $5,178 reported for 2025 was more than what 86% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,442 · 2020: $5,147 · 2021: $4,167 · 2022: $3,738 · 2023: $6,086 · 2024: $1,928 · 2025: $5,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,283 · Travel and Lodging: $2,869 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,750 · Honoraria: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,283.35 |
| Travel and Lodging | $2,868.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,750.00 |
| Honoraria | $1,290.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $6,423.91 | 2019-2023 | Zolgensma |
| Genentech, INC. | $4,823.69 | 2023-2025 | Evrysdi |
| Sarepta Therapeutics, INC. | $3,361.87 | 2019-2025 | Elevidys |
| Biogen, INC. | $3,236.40 | 2019-2025 | Spinraza, Skyclarys |
| Acadia Pharmaceuticals INC | $2,308.53 | 2023-2025 | Daybue |
| Itf Therapeutics LLC | $1,491.14 | 2024-2025 | |
| Ucb, INC. | $1,111.97 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Neuropace, INC. | $775.36 | 2020 | |
| Livanova USA, INC. | $698.87 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Ptc Therapeutics, INC. | $589.75 | 2019-2024 | Emflaza |
| Neurelis, INC. | $587.06 | 2020-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $515.55 | 2019-2025 | |
| Ns Pharma, INC. | $420.66 | 2021-2025 | Viltepso |
| Eisai INC. | $416.47 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $366.08 | 2024-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymund David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.